Analysis of PRO1_, NFkappaB, and PRO2_ Pathways in Contribution to the Growth and Survival of Lymphoma Cells
(A-D) Immunoblot analysis of wild-type and PRO3_ transgenic lymphomas for PRO4_, NFkappaB, and PRO5_ signaling after treatment with (A) an PRO6_ inhibitor, triciribine, (B)] an NFkappaB inhibitor, BAY11-7085, and the PRO7_ inhibitors (C) cucurbitacin I and (D) AG490, at the indicated concentrations.
[Analysis;of;PRO1_, NFkappaB, and PRO2_ Pathways] 

[and@1; ;PRO1_]
[and@1; ;NFkappaB 

[and@1; ;Pathways] 

[Pathways; ;PRO2_] 

[Pathways;in; ]   

[Growth; ;the@1] 

[and@2; ;Growth] 

[and@2; ;Survival] 

[Survival;of;Cells] 

[Cells; ;Lymphoma] 

[analysis; ;Immunoblot]
[analysis;of;lymphomas] 

[and@3; ;wild-type] 

[and@3; ;PRO3_ transgenic] 

[lymphomas; ;transgenic] 

[lymphomas; ;PRO3_] 

[lymphomas; ;wild-type] 

[lymphomas;for;signaling]
[signaling; ;PRO4_, NFkappaB, and PRO5_] 
[and@4; ;PRO4_] 

[and@4; ;NFkappaB] 

[and@4; ;PRO5_] 

[signaling;after;treatment] 

[treatment;with;inhibitor] 

[and@5; ;PRO6_ inhibitor] 

[and@5; ;PRO7_ inhibitors] 

[and@5; ;NFkappaB inhibitor] 

[PRO6_ inhibitor; ;triciribine] 

[PRO6_ inhibitor; ;an] 

[NFkappaB inhibito; ;BAY11-7085] 

[NFkappaB inhibito; ;an] 

[PRO7_ inhibitors; ;the@2] 
[PRO7_ inhibitors; ;cucurbitacin I and (D) AG490] 

[and@6; ;cucurbitacin I] 

[and@6; ;AG490] 

[treatment;at;concentrations] 

[concentrations; ;indicated] 

[concentrations; ;the@3] 

